Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Subscribe To Our Newsletter & Stay Updated
